Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
==== First-pass metabolism ==== During a typical drinking session, approximately 90% of the metabolism of ethanol occurs in the liver. Alcohol dehydrogenase and aldehyde dehydrogenase are present at their highest concentrations (in liver mitochondria). But these enzymes are widely expressed throughout the body, such as in the stomach and small intestine. Some alcohol undergoes a first pass of metabolism in these areas, before it ever enters the bloodstream.
Thermodynamics is concerned with heat and temperature and their relation to energy and work. It defines macroscopic variables, such as internal energy, entropy, and pressure, that partly describe a body of matter or radiation. It states that the behavior of those variables is subject to general constraints common to all materials. These general constraints are expressed in the four laws of thermodynamics. Thermodynamics describes the bulk behavior of the body, not the microscopic behaviors of the very large numbers of its microscopic constituents, such as molecules. The behavior of these microscopic particles is described by, and the laws of thermodynamics are derived from, statistical mechanics. The study of thermodynamics is fundamental to materials science. It forms the foundation to treat general phenomena in materials science and engineering, including chemical reactions, magnetism, polarizability, and elasticity. It explains fundamental tools such as phase diagrams and concepts such as phase equilibrium.
=== Thailand === In Thailand, postgraduate medical training is monitored by the Medical Council of Thailand (TMC) and conducted by their respective "Royal Colleges". Thailand has a significant issue with an imbalance of medical personnel between Bangkok and the remaining 76 provinces. As a primate city, the majority of specialists wish to remain in Bangkok after training. Each year, the TMC outlines the requirements for application to a certain specialty, depending on the needs of the country for staff within that field. Specialities are therefore classified into tiers depending on national demand. The duration spent in the national internship program depends on the specialty the graduate wishes to study. Specialties classified as 'lacking' may require only one year of internship, whilst more competitive specialties often require the full three-year duration of internship to meet the application criteria. Fields classified as 'severely lacking' may not require internship training at all. Application to residency may be done on contract with a government hospital or without a contract, namely 'free-training'. Government hospitals may sign contracts to sponsor residency training for specialist doctors they require. In these cases, the duration for internship required in more popular fields may be reduced. For example, a residency in internal medicine requires three years of internship if applying without contract, but is reduced to two years if applying under contract.
In addition to his academic work, Baran also holds many accolades in industry as a scientific entrepreneur, company co-founder, consultant and scientific advisor. He co-founded his first company Sirenas Marine Discovery in 2012 alongside Eduardo Esquenazi and Jake Beverage —a company that is focused on marine-inspired small molecules and pre-clinical leads for cancer, HIV, and infectious diseases. In 2016, he joined forces with fellow Scripps colleagues, Benjamin F. Cravatt and Jin-Quan Yu to co-found Vividion Therapeutics with the goal of identifying small molecules that bind currently undrugged targets via a covalent-first chemoproteomics approach. Vividion was sold to Bayer in 2021 for up to $2 billion ($1.5 billion with an additional $500 million in milestone payments). In the same year, Baran founded Elsie Biotechnologies, an antisense oligonucleotide (ASO)-based company with the goal of discovering therapeutic agents that can achieve desirable medicinal effects not attainable with existing drugs by modulating gene expression of DNA or RNA. Elsie Biotechnologies was sold to GlaxoSmithKline (GSK) in 2024 for $50 million. Baran also co-founded and is on the scientific advisory team of Galileo Biosystems, a preclinical stage biopharmaceutical company focused on developing therapeutic agents for inflammatory and autoimmune diseases.
Diazepam is a medication with a high risk of misuse and can cause drug dependence. Some pharmacologists recommend urgent action by national governments to improve prescribing patterns of benzodiazepines such as diazepam. A single dose of diazepam modulates the dopamine system in similar ways to how morphine and alcohol modulate the dopaminergic pathways. Between 50 and 64% of rats will self-administer diazepam. Diazepam can substitute for the behavioral effects of barbiturates in a primate study. Diazepam has been found as an adulterant in heroin. Diazepam drug misuse can occur either through recreational misuse, where the drug is taken to achieve a high, or when the drug is continued long term against medical advice. Sometimes, it is used by stimulant users to "come down" and sleep and to help control the urge to binge. These users often escalate dosage from 2 to 25 times the therapeutic dose of 5 mg to 10 mg. A large-scale study in the US, conducted by SAMHSA, using data from 2011, determined that benzodiazepines were present in 28.7% of emergency department visits involving nonmedical use of pharmaceuticals. In this regard, benzodiazepines are second only to opiates, the study found in 39.2% of visits. About 29.3% of drug-related suicide attempts involve benzodiazepines, making them the most frequently represented class in drug-related suicide attempts. Males misuse benzodiazepines as commonly as females.
Sources: en.wikipedia.org
== References == Aeschliman, M.D (28 March 2005). "Murderous Science". The National Review. Vol. LVII, no. 5. pp. 49–50. Baldwin, Peter (1990). Reworking the Past: Hitler, the Holocaust, and the Historians' Debate. Boston: Beacon Press. Bessel, Richard (August 1990). "Detlev J.K. Peukert". German History. 8 (3): 321–324. doi:10.1093/gh/8.3.321. Crew, David (May 1992). "The Pathologies of Modernity: Detlev Peukert on Germany's Twentieth Century". Social History. 17 (2): 319–328. doi:10.1080/03071029208567840. Kater, Michael (May 1992). "Conflict in Society and Culture: The Challenge of National Socialism". German Studies Review. 15 (2): 289–294. doi:10.2307/1431167. JSTOR 1431167. Kershaw, Ian (2000). The Nazi Dictatorship Problems and Perspectives of Interpretation. London: Arnold Press. ISBN 0-340-76028-1. Lindemann, Albert (February 1982). "Review of Die KPD im Widerstand Verfolgung und Untergrundarbeit am Rhein und Ruhr, 1933-1945". The American Historical Review. 82 (1): 205. doi:10.2307/1863393. JSTOR 1863393. Nolan, Mary (Spring–Summer 1988). "The Historikerstreit and Social History". New German Critique (44): 1–80. Pendas, Devin; Roseman, Mark (2017). Beyond the Racial State: Rethinking Nazi Germany. Cambridge: Cambridge University Press. ISBN 978-1107165458. Peukert, Detlev (1987). Conformity, Opposition and Racism in Everyday Life. New Haven: Yale University Press. ISBN 0300038631. Peukert, Detlev (1994). "The Genesis of the 'Final Solution' from the Spirit of Science". In Thomas Childers; Jane Caplan (eds.). Reevaluating the Third Reich. New York: Holmes & Meier.
Wikimedia Atlas of Singapore Official website Singapore Government Portal Geographic data related to Singapore at OpenStreetMap Singapore Department of Statistics "Key Facts & Figures". Ministry of Transport, Singapore. Retrieved 11 January 2003. Ministry of Foreign Affairs, Government of Singapore WikiSatellite view of Singapore at WikiMapia "About Us" from Singapore's National Library Board; numerous well-researched and well-documented essays on key events and important figures, as well as topics regarding culture, architecture, nature, etc. Singapore profile from the BBC News
=== Duplicate private keys === Collision (two or more wallets having the same private key) is theoretically possible, since keys can be generated without being used for transactions, and are therefore offline until recorded in the blockchain ledger. However, this possibility is effectively negated because the theoretical probability of two or more private keys being the same is extremely low. The number of possible wallets and thus private keys is extremely high, so duplicating or hacking a certain key would be inconceivable.
Peptide ion channel blockers Low molecular weight compounds Therapeutics There are only two peptide toxins that selectively block P-type channels: ω-agatoxin IVA and ω-agatoxin IVB. The other blockers mentioned, such as the low molecular weight and therapeutic blockers, are nonselective. This means they can act on P-type channels as well as other channels.
=== Clinical exposure === Gliotoxin is toxic if swallowed or inhaled, and can cause skin and eye irritation if exposure occurs to these areas. The oral LD50 of gliotoxin is 67 mg/kg. Acute symptoms of gliotoxin start rapidly after ingestion.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.